NervGen Pharma (NASDAQ:NGEN – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.05), Zacks reports.
NervGen Pharma Stock Up 3.2%
NASDAQ:NGEN traded up $0.06 during midday trading on Monday, reaching $1.94. 178,377 shares of the stock traded hands, compared to its average volume of 514,070. The business has a fifty day moving average of $1.74. NervGen Pharma has a 12 month low of $1.28 and a 12 month high of $6.30. The firm has a market capitalization of $156.42 million and a PE ratio of -4.18.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on NGEN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NervGen Pharma in a research note on Monday, November 2nd. Wall Street Zen raised shares of NervGen Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.
NervGen Pharma Company Profile
NervGen Pharma is a clinical-stage biotechnology company focused on developing treatments for nervous system injuries and diseases. The company’s research centers on ways to support nerve repair and restore function after damage to the nervous system. Its lead investigational product, NVG-291, is a peptide designed to target a protein involved in limiting nerve repair. NervGen has studied the candidate for spinal cord injury and is exploring its potential in other conditions involving nervous system damage.
Featured Articles
- Five stocks we like better than NervGen Pharma
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
